Sean Ainsworth
Direktor/Vorstandsmitglied bei OCUPHIRE PHARMA, INC.
Vermögen: 72 475 $ am 30.04.2024
Profil
Sean Ainsworth is the founder of Compendia Bioscience, RetroSense Therapeutics LLC, Ainsworth Bioconsulting LLC, and Ray Therapeutics, Inc. Compendia Bioscience was founded in 2006, RetroSense Therapeutics LLC was founded in 2009, Ainsworth Bioconsulting LLC was founded in 2004, and Ray Therapeutics, Inc. was founded in 2021.
Mr. Ainsworth's titles held at RetroSense Therapeutics LLC and Ray Therapeutics, Inc. are Chairman & Chief Executive Officer and Chairman, respectively.
Mr. Ainsworth's current jobs are Chairman & Chief Executive Officer at Immusoft Corp.
and Lead Independent Director at Ocuphire Pharma, Inc. Mr. Ainsworth's former job was Chief Executive Officer at Genevivo LLC.
Mr. Ainsworth received an MBA degree from Washington University in St. Louis in 2002 and an undergraduate degree from the University of California San Diego in 1996.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OCUPHIRE PHARMA, INC.
0,19% | 15.04.2024 | 47 215 ( 0,19% ) | 72 475 $ | 30.04.2024 |
Aktive Positionen von Sean Ainsworth
| Unternehmen | Position | Beginn |
|---|---|---|
| OCUPHIRE PHARMA, INC. | Direktor/Vorstandsmitglied | 01.04.2018 |
RetroSense Therapeutics LLC
 RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Vorstandsvorsitzender | 01.01.2009 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Vorstandsvorsitzender | 05.01.2018 |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Gründer | 01.01.2021 |
Ehemalige bekannte Positionen von Sean Ainsworth
| Unternehmen | Position | Ende |
|---|---|---|
| Ainsworth Bioconsulting LLC | Gründer | 01.06.2012 |
Compendia Bioscience, Inc.
 Compendia Bioscience, Inc. Information Technology ServicesTechnology Services Compendia Bioscience, Inc. provides information solutions for oncology drug discovery. The company was founded by Daniel D. Rhodes and Arul Chinnaiyan in February 2006 and is headquartered in Canton, MI. | Gründer | - |
| Genevivo LLC | Vorstandsvorsitzender | - |
Ausbildung von Sean Ainsworth
| University of California San Diego | Undergraduate Degree |
| Washington University in St. Louis | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OCUPHIRE PHARMA, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
RetroSense Therapeutics LLC
RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
| Ainsworth Bioconsulting LLC | |
| Genevivo LLC | |
Compendia Bioscience, Inc.
Compendia Bioscience, Inc. Information Technology ServicesTechnology Services Compendia Bioscience, Inc. provides information solutions for oncology drug discovery. The company was founded by Daniel D. Rhodes and Arul Chinnaiyan in February 2006 and is headquartered in Canton, MI. | Technology Services |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
